At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 54 enrolled
Drug / intervention
exenatide +1 moredrug
Likely dose
exenatide 5mcgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Study to Assess the Effect of Exenatide Treatment on Mean 24-Hour Heart Rate in Patients With Type 2 Diabetes
In Brief
A Phase 3 clinical trial evaluating exenatide and placebo for Type 2 Diabetes Mellitus. Completed, enrolled 54 participants across 6 sites in 2 countries.
Detailed Summary
This study will explore the effect of exenatide (given twice a day) versus placebo (given twice a day) treatment on change in mean 24-hour heart rate over a 12 week period of drug exposure in patients with type 2 diabetes.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 2 Diabetes Mellitus
CountriesCanada, Netherlands
CollaboratorsEli Lilly and Company
Timeline
Phase 3CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedAug 2007
Enrollment StartSep 2007
Primary CompletionApr 2008
TodayJul 2026
First PostedAug 14, 2007
Enrollment StartSep 1, 2007
Primary CompletionApr 1, 2008
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 18.9 years ago
Interventions
exenatidedrug
subcutaneous injection, 5mcg or 10mcg, twice a day
placebodrug
subcutaneous injection, volume equivalent to active, twice a day